Regulus Therapeutics Inc (NASDAQ: RGLS) released topline results from the first cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) trial of RGLS8429 for Autosomal Dominant Polycystic
https://news.kraftheinzcompany.com/press-releases-details/2023/Kraft-Heinz-issues-voluntary-recall-of-select-Kraft-Singles-American-Processed-Cheese-Slices/default.aspxKraft Heinz is announcing a voluntary recall of